Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples